VFC Resolution Update: Dengue Vaccines

Jeanne Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
June 24, 2021
The purpose of this resolution is to add a vaccine for the prevention of Dengue to the VFC program.
Eligible Groups

Children aged 9-16 years of age with laboratory confirmation of previous dengue infection and living in endemic areas (i.e., Puerto Rico, American Samoa, and the US Virgin Islands).

- This VFC resolution will be updated, as necessary, if dengue-endemic areas in the US or its territories change.
Recommended Vaccination Schedule, Intervals, and Dosage

Recommended Vaccination Schedule and Intervals

- Three doses administered 6 months apart at 0, 6, and 12 months

Recommended Dosage

- Refer to product package inserts
Contraindications and Precautions

- Contraindications and Precautions can be found in the package inserts available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states
Statement Regarding Update Based on Published Documents

- [If an ACIP recommendation regarding dengue vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the URL.]